Oral Antihyperglycemic Treatment Options for Type 2 Diabetes Mellitus

Medical Clinics of North America

Volumn 99, Issue 1, 2015, Pages 87-106

  Brietzke, Stephen A ^a  

^a University of Missouri   (United States)

Author keywords

Bromocriptine; Colesevelam; Metformin; Sodium glucose transporter 2 inhibitors (SGLT2 inhibitors); Sulfonylureas; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BROMOCRIPTINE; COLESEVELAM; GLIBENCLAMIDE; GLIMEPIRIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; HEALTH HAZARD; HUMAN; LOW DRUG DOSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG COST; DRUG MONITORING; ECONOMICS; HYPOGLYCEMIA; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG COSTS; DRUG MONITORING; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84914159859     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2014.08.012     Document Type: Review

References (120)

1. Miller R.A., Birnbaum M.J. An energetic tale of AMPK-independent effects of metformin. JClin Invest 2010, 120:2267-2270.
2. Andujar-Plata P., Pi-Sunyer X., Laferrere B. Metformin effects revisited. Diabetes Res Clin Pract 2012, 95:1-9.
3. United Kingdom Prospective Diabetes Study Group United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310:83-88.
4. DeFronzo R.A., Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. Multicenter Metformin Study Group. NEngl J Med 1995, 333:541-549.
5. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. NEngl J Med 2008, 359:1577-1589.
6. Hemmingsen B., Christensen L.L., Wetterslev J., et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomized clinical trials with meta-analyses and trial sequential analyses. BMJ 2012, 344:e1771.
7. Soranna D., Scotti L., Zambon A., et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012, 17:813-822.
8. Libby G., Donnelly L.A., Donnan P.T., et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32:1620-1625.
9. Bodmer M., Meier C., Krahenbuhl S., et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010, 33:1304-1308.
10. Jiralerspong S., Palla S.L., Giordano S.H., et al. 2009 Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. JClin Oncol 2009, 27:3297-3302.
11. Li D., Yeung S.C., Hassan M.M., et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:482-488.
12. Wright J.L., Stanford J.L. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009, 20:1617-1622.
13. Bouchoucha M., Uzza B., Cohen R. Metformin and digestive disorders. Diabetes Metab 2010, 37:90-96.
14. de Jager J., Kooy A., Lehert P., et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010, 340:c2181.
15. Anonymous Metformin for non-insulin-dependent diabetes mellitus. Med Lett Drugs Ther 1995, 37:41-42.
16. Lipska K.J., Bailey C.J., Inzucchi S.E. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011, 34:1431-1437.
17. Salpeter S.R., Greyber E., Pasternak G.A., et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes. Cochrane Database Syst Rev 2010, (4). CD002967.
18. Scheen A.J., Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013, 39:179-190.
19. Eurich D.T., Majumdar S.R., McAlister F.A., et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28:2345-2351.
20. Nye H.J., Herrington W.G. Metformin: the safest hypoglycaemic agent in chronic kidney disease?. Nephron Clin Pract 2011, 118:c380-c383.
21. Rocha A., Almeda M., Santos J., et al. Metformin in patients with chronic kidney disease: strengths and weaknesses. JNephrol 2013, 26:55-60.
22. Seino S. Cell signaling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia 2012, 55:2096-2108.
23. Ashcroft F.M. ATP-sensitive potassium channelopathies: focus on insulin secretion. JClin Invest 2005, 115:2047-2058.
24. Hemmingsen B., Schroll J.B., Lund S.S., et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus (review). Cochrane Database Syst Rev 2013, (4). CD009008.
25. Bell D.S. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004, 26:1715-1727.
26. Davis S.N. The role of glimepiride in the effective management of type 2 diabetes. JDiabetes Complications 2004, 18:367-376.
27. Hirst J.A., Farmer A.J., Dyar A., et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013, 56:973-984.
28. Turner R.C., Cull C.A., Frighi V., et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
29. Del Prato S., Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006, 55(Suppl 1):S20-S27.
30. Holman R.R. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 2006, 55(Suppl 1):S2-S5.
31. Kahn S.E., Haffner S.M., Helse M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. NEngl J Med 2006, 355:2427-2443.
32. Rambiritch V., Naidoo P., Butkow N. Dose-response relationships of sulfonylureas: will doubling the dose double the response?. South Med J 2007, 100:1132-1136.
33. Goldberg R.B., Holvey S.M., Schneider J. Adose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996, 19:849-856.
34. Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes-brief overview. Diabetes 2004, 53(Suppl 3):S151-S155.
35. Horton E.S., Whitehouse F., Ghazzi M.N., et al. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care 1998, 21:1462-1469.
36. Holstein A., Plaschke A., Egberts E.H. Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001, 17:467-473.
37. United Kingdom Prospective Diabetes Study Group United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998, 128:165-175.
38. Caritis S.N., Hebert M.F. Apharmacologic approach to the use of glyburide in pregnancy. Obstet Gynecol 2013, 121:1309-1312.
39. Dhulkotia J.S., Ola B., Fraser R., et al. Oral hypoglycemic agents versus insulin in management of gestational diabetes: a systematic review and meta-analysis. Am J Obstet Gynecol 2010, 203:457.e1-457.e9.
40. Goldner M.G., Knatterud G.L., Prout T.E. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971, 218:1400-1410.
41. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
42. Roumie C.L., Hung A.M., Greevy R.A., et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus. Ann Intern Med 2012, 157:612-615.
43. + channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004, 53(Suppl 3):S156-S164.
44. Nagashima K., Takahashi A., Ikeda H., et al. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmacological properties and tissue selectivity. Diabetes Res Clin Pract 2004, 66(Suppl 1):S75-S78.
45. Thisted H., Johnsen S.P., Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism 2006, 55(Suppl 1):S16-S19.
46. Lee T.M., Chou T.F. Impairment of myocardial protection in type 2 diabetic patients. JClin Endocrinol Metab 2003, 88:531-537.
47. Zeller M., Danchin N., Simon D., et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. JClin Endocrinol Metab 2010, 95:4993-5002.
48. Singh S., Singh P.P., Singh A.G., et al. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013, 108:881-891.
49. Chang C.H., Lin J.W., Wu L.C., et al. Oral insulin secretogogues, insulin, and cancer risk in type 2 diabetes mellitus. JClin Endocrinol Metab 2012, 97:E1170-E1175.
50. Thakkar B., Aronis K.N., Vamvini M.T., et al. Metformin and sulfonylureas in relation to cancer risk in type 2 diabetes patients: a meta-analysis using primary data of published studies. Metabolism 2013, 62:922-934.
51. Riddle M.C. Editorial: sulfonylureas differ in effects on ischemic preconditioning-is it time to retire glyburide?. JClin Endocrinol Metab 2003, 88:528-530.
52. Riddle M.C. Editorial: more reasons to say goodbye to glyburide. JClin Endocrinol Metab 2010, 95:4867-4870.
53. Anonymous Repaglinide for type 2 diabetes. Med Lett Drugs Ther 1998, 40:55-56.
54. Anonymous Nateglinide for type 2 diabetes. Med Lett Drugs Ther 2001, 43:29-31.
55. Cariou B., Charbonnel B., Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab 2012, 23:205-215.
56. Decker M., Hofflich H., Elias A.N. Thiazolidinediones and the preservation of β-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab 2008, 10:617-625.
57. Ovalle F., Ovalle-Berumen J.F. Thiazolidinediones: a review of their benefits and risks. South Med J 2002, 95:1188-1194.
58. Diamant M., Heine R.J. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003, 63:1373-1405.
59. Derosa G., Maffioli P. Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. Diabetes Res Clin Pract 2011, 91:265-270.
60. Viberti G. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes. JDiabetes Complications 2005, 19:168-177.
61. Riera-Guardia N., Rothenbacher D. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab 2008, 10:367-375.
62. Quinn C.E., Hamilton P.K., Lockhart C.J., et al. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 2008, 153:636-645.
63. Lebovitz H.E. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol 2002, 90(Suppl):34G-41G.
64. Kendall D.M. Thiazolidinediones-the case for early use. Diabetes Care 2006, 29:154-157.
65. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008, 24:14-26.
66. Choi D., Kim S.K., Choi S.H., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004, 27:2654-2660.
67. Gilling L., Suwattee P., DeSouza C., et al. Effects of thiazolidinediones on cardiovascular risk factors. Am J Cardiovasc Drugs 2002, 2:149-156.
68. Wyne K.L. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy. Diabetes Obes Metab 2006, 8:365-380.
69. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001, 134:61-71.
70. Yki-Jarvinen H. Thiazolidinediones and the liver in humans. Curr Opin Lipidol 2009, 20:477-483.
71. Khanderia U., Pop-Busui R., Eagle K.A. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Ann Pharmacother 2008, 42:1466-1474.
72. Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet 2007, 370:1129-1136.
73. DREAM Trial Investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368:1096-1105.
74. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): a multicenter, randomized, open-label trial. Lancet 2009, 373:2125-2135.
75. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. NEngl J Med 2007, 356:2457-2471.
76. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomized controlled trial. Lancet 2005, 266:1279-1289.
77. Loke Y.K., Kwok C.S., Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011, 342:d1309.
78. Bosetti C., Rosato V., Buniato D., et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013, 18:148-156.
79. Schwartz A.V., Sellmeyer D.E., Vittinghoff E., et al. Thiazolidinedione use and bone loss in older diabetic adults. JClin Endocrinol Metab 2006, 91:3349-3354.
80. Aubert R.E., Herrera V., Chen W., et al. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 2010, 12:716-721.
81. Meier C., Kraenzlin M.E., Bodmer M., et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008, 168:820-825.
82. Dormuth C.R., Carney G., Carleton B., et al. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009, 169:1395-1402.
83. Kahn S.E., Zinman B., Lachin J.M., et al. Rosiglitazone-associated fractures in type 2 diabetes. An analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845-851.
84. Loke Y.K., Singh S., Furberg C.D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009, 180:32-39.
85. Diamant M., Morsink L.M. SGLT2 inhibitors for diabetes: turning symptoms into therapy. Lancet 2013, 382:917-918.
86. Nair S., Wilding J.P. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. JClin Endocrinol Metab 2010, 95:34-42.
87. Stenlof K., Cefalu W.T., Kim K.A., et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013, 15:372-382.
88. Cefalu W.T., Leiter L.A., Yoon K.H., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013, 382:941-950.
89. Schernthaner G., Gross J.L., Rosenstock J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea-a 52-week randomized trial. Diabetes Care 2013, 36:2508-2515.
90. Bailey C.F., Gross J.L., Pieters A., et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:2223-2233.
91. Vasilakou D., Karagiannis T., Athanasiadou E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013, 159:262-274.
92. Stack C.B., Localio R., Griswold M.E., et al. Handling of rescue and missing data affects synthesis and interpretation of evidence: the sodium-glucose cotransporter 2 inhibitor example. Ann Intern Med 2013, 159:285-288.
93. Neal B., Perkovic V., de Zeeuw D., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013, 166:217-223.
94. Anonymous Canagliflozin for type 2 diabetes. Med Lett Drugs Ther 2013, 55:37-39.
95. Anonymous Acarbose for diabetes mellitus. Med Lett Drugs Ther 1996, 38:9-10.
96. Gross J.L., Kramer C.K., Leitao C.B., et al. Effect of antihyperglycemic agents added to metformin and sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011, 154:672-679.
97. Coniff R.F., Shapiro J.A., Robbins D., et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care 1995, 18:817-824.
98. Chiasson J.L., Josse R.G., Hunt J.A., et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994, 121:928-935.
99. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002, 359:2072-2077.
100. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 2003, 290:486-494.
101. Cheng A.Y., Fantus I.G. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005, 172:213-226.
102. Reasner C.A. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. JCardiovasc Pharmacol 2008, 52:136-144.
103. Zieve F.J., Kalin M.F., Schwartz S.L., et al. Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007, 29:74-83.
104. Bays H.E., Goldberg R.B., Truitt K.E., et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin. Glucose and lipid effects. Arch Intern Med 2008, 168:1975-1983.
105. Fonseca V.A., Rosenstock J., Wang A.C., et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008, 31:1479-1484.
106. Goldberg R.B., Fonseca V.A., Truitt K.E., et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008, 168:1531-1540.
107. Ooi C.P., Loke S.C. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev 2012, (12). CD009361. 10.1002/14651858.CD009361.pub2.
108. Smushkin G., Sathananthan M., Piccinini F., et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes 2013, 62:1094-1101.
109. Aggarwal S., Loomba R.S., Arora R.R. Efficacy of colesevelam on lowering glycemia and lipids. JCardiovasc Pharmacol 2012, 59:198-205.
110. Goldfine A.B. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Curr Opin Cardiol 2008, 23:502-511.
111. DeFronzo R.A. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011, 34:789-794.
112. Cincotta A.H., Meier A.H., Cincotta M. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999, 8:1683-1707.
113. Kerr J.L., Timpe E.M., Petkewicz K.A. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Ann Pharmacother 2010, 44:1777-1786.
114. Vinik A.I., Cincotta A.H., Scranton R.E., et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract 2012, 18:931-943.
115. Gaziano J.M., Cincotta A.H., O'Connor C.M., et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010, 33:1503-1508.
116. Gaziano J.M., Cincotta A.H., Vinik A., et al. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. JAm Heart Assoc 2012, 1:e002279. 10.1161/JAHA.112.002279.
117. Bell D.S. Why does quick-release bromocriptine decrease cardiac events?. Diabetes Obes Metab 2011, 13:880-884.
118. Garber A.J., Blonde L., Bloomgarden Z.T., et al. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract 2013, 19:100-106.
119. Anonymous Bromocriptine (Cycloset) for type 2 diabetes. Med Lett Drugs Ther 2010, 52:97-99.
120. Bennett W.L., Maruthur N.M., Singh S., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011, 154:602-613.